{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T23:04:07Z","timestamp":1771196647254,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103667","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T22:35:57Z","timestamp":1771194957000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Use of Chimeric Antigen Receptor T-cell (CAR-T) Therapy With Lisocabtagene Maraleucel in a Renal Transplant Recipient With Refractory\/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)"],"prefix":"10.7759","author":[{"given":"Waqqas","family":"Tai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesreen","family":"Shahrour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afoma","family":"Anyadibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuoluwa","family":"Oyetoran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Gopishetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Precious","family":"Idogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip","family":"Samarapungavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jassim H","family":"Sarmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishmael","family":"Jaiyesimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li S","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018, 50:74-87. 10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920963","article-title":"Relapsed or refractory diffuse large B-cell lymphoma: \"dazed and confused\"","volume":"36","author":"Kesireddy M","year":"2022","unstructured":"Kesireddy M, Lunning M. Relapsed or refractory diffuse large B-cell lymphoma: \"dazed and confused\". Oncology (Williston Park). 2022, 36:366-75. 10.46883\/2022.25920963","journal-title":"Oncology (Williston Park)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al.. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019, 20:31-42. 10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster SJ","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al.. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021, 22:1403-15. 10.1016\/S1470-2045(21)00375-2","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson JS","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al.. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024, 143:404-16. 10.1182\/blood.2023020854","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell PA","year":"2025","unstructured":"Riedell PA, Grady CB, Nastoupil LJ, et al.. Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025, 9:1232-41. 10.1182\/bloodadvances.2024014164","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111987","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?","volume":"16","author":"Str\u00fc\u00dfmann T","year":"2024","unstructured":"Str\u00fc\u00dfmann T, Marks R, W\u00e4sch R. Relapsed\/refractory diffuse large B-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?. Cancers (Basel). 2024, 16:1987. 10.3390\/cancers16111987","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan M","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009, 50:1257-60. 10.1080\/10428190903040048","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar M","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al.. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022, 399:2294-308. 10.1016\/S0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal A","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, et al.. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncology. 2022, 23:1066-77. 10.1016\/S1470-2045(22)00339-4","journal-title":"Lancet Oncology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01418-0","article-title":"Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder","volume":"25","author":"Lee M","year":"2023","unstructured":"Lee M, Abousaud A, Harkins RA, et al.. Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder. Curr Oncol Rep. 2023, 25:883-95. 10.1007\/s11912-023-01418-0","journal-title":"Curr Oncol Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna M","year":"2023","unstructured":"McKenna M, Epperla N, Ghobadi A, et al.. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD. Br J Haematol. 2023, 202:248-55. 10.1111\/bjh.18828","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-hodgkin's lymphoma","volume":"15","author":"Ying Z","year":"2019","unstructured":"Ying Z, He T, Wang X, et al.. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-hodgkin's lymphoma. Mol Ther Oncolytics. 2019, 15:60-8. 10.1016\/j.omto.2019.08.002","journal-title":"Mol Ther Oncolytics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy S","year":"2021","unstructured":"Krishnamoorthy S, Ghobadi A, Santos RD, et al.. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am J Transplant. 2021, 21:809-14. 10.1111\/ajt.16367","journal-title":"Am J Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli E","year":"2021","unstructured":"Melilli E, Mussetti A, Linares GS, et al.. Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient. Kidney Med. 2021, 3:665-8. 10.1016\/j.xkme.2021.03.011","journal-title":"Kidney Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01907-z","article-title":"CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review","volume":"58","author":"Portuguese AJ","year":"2023","unstructured":"Portuguese AJ, Gauthier J, Tykodi SS, Hall ET, Hirayama AV, Yeung CC, Blosser CD. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplant. 2023, 58:353-9. 10.1038\/s41409-022-01907-z","journal-title":"Bone Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk O","year":"2021","unstructured":"Mamlouk O, Nair R, Iyer SP, et al.. Safety of CAR T-cell therapy in kidney transplant recipients. Blood. 2021, 137:2558-62. 10.1182\/blood.2020008759","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2021.103304","article-title":"CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review","volume":"69","author":"Hernani R","year":"2021","unstructured":"Hernani R, Sancho A, Amat P, et al.. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Curr Res Transl Med. 2021, 69:103304. 10.1016\/j.retram.2021.103304","journal-title":"Curr Res Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001584","article-title":"CAR T-cell therapy for refractory posttransplantation lymphoproliferative disorder in a kidney transplant patient","volume":"10","author":"Guy P","year":"2024","unstructured":"Guy P, Marion O, Oberic L, Darres A, Cointault O, Del Bello A, Kamar N. CAR T-cell therapy for refractory posttransplantation lymphoproliferative disorder in a kidney transplant patient. Transplant Direct. 2024, 10:e1584. 10.1097\/TXD.0000000000001584","journal-title":"Transplant Direct"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01145-1","article-title":"Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series","volume":"56","author":"Luttwak E","year":"2021","unstructured":"Luttwak E, Hagin D, Perry C, et al.. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transplant. 2021, 56:1031-7. 10.1038\/s41409-020-01145-1","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13861","article-title":"Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy","volume":"25","author":"Dang BN","year":"2021","unstructured":"Dang BN, Ch'ng J, Russell M, Cheng JC, Moore TB, Alejos JC. Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy. Pediatr Transplant. 2021, 25:e13861. 10.1111\/petr.13861","journal-title":"Pediatr Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/423666-successful-use-of-chimeric-antigen-receptor-t-cell-car-t-therapy-with-lisocabtagene-maraleucel-in-a-renal-transplant-recipient-with-refractoryrelapsed-diffuse-large-b-cell-lymphoma-dlbcl","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T22:35:58Z","timestamp":1771194958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/423666-successful-use-of-chimeric-antigen-receptor-t-cell-car-t-therapy-with-lisocabtagene-maraleucel-in-a-renal-transplant-recipient-with-refractoryrelapsed-diffuse-large-b-cell-lymphoma-dlbcl"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.103667","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}